RxDoctor Payments Data

Nimi Patel

Neurology · Waycross, GANPI 1235410911

Payments from drug & device makers

$5,527in general payments, 2019–2025

Across 287 payments — averaging $19.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$756
  • Teva Pharmaceuticals USA, Inc.$602
  • Pfizer$597
  • UCB, Inc.$354
  • AstraZeneca$261
  • Argenx US, Inc.$233
  • plus $3K from 38 others

What the payments were for

  • Speaking & faculty fees$421%
  • Food & beverage$5,11893%
  • Education$3677%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,527 in reported general payments places this provider in the 65th percentile of 506 neurology providers in Georgia.

See all neurology providers in Georgia

Medicare billing

Part B allowed, 2024
$150,271
Medicare patients
503
Services billed
1,076

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5030$514,662
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5020$491,816
EvrysdiRisdiplam18$481,475
Gamunex-CImmune Globul G/Gly/Iga Avg 4613$362,077
Austedo XrDeutetrabenazine18$117,041
QuliptaAtogepant73$97,463
BotoxOnabotulinumtoxina59$79,317
Nurtec OdtRimegepant Sulfate41$72,064
UbrelvyUbrogepant43$55,573
GlatopaGlatiramer Acetate11$26,960
NamzaricMemantine Hcl/Donepezil Hcl24$20,896
Emgality SyringeGalcanezumab-Gnlm19$14,577
Aimovig AutoinjectorErenumab-Aooe17$12,509
Carbidopa-LevodopaCarbidopa/Levodopa159$3,816
Pramipexole ErPramipexole Di-Hcl11$3,490

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$63$514,66230 claims
CSL BehringPrivigen$125$491,81620 claims
Genentech USA, Inc.Evrysdi$199$481,47518 claims
AbbVieQulipta, Botox, Ubrelvy, Namzaric$756$253,249199 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$602$117,04118 claims
PfizerNurtec Odt$597$72,06441 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$63$2,38814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 506 neurology providers in Georgia.

Other neurology in Waycross

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →